XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
AstraZeneca Agreements [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 $ (171,516)
Additions (36,184)
Currency Translation and Other 1,227
Recognized as Revenue 35,959
Balance at June 30, 2022 (170,514)
Product Revenue, Net [Member] | Direct Sales [Member] | Contract Liabilities [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (3,176)
Additions (286)
Deduction 1,903
Currency Translation and Other 157
Balance at June 30, 2022 (1,402)
Drug Product Revenue [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (39,036)
Additions (74,635)
Reclassified to Accrued Liability 58,644
Recognized as Revenue 90
Balance at June 30, 2022 (54,937)
Drug Product Revenue [Member] | AstraZeneca Agreements [Member] | U.S. [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (11,171)
Additions 0
Reclassified to Accrued Liability 11,171
Recognized as Revenue 0
Balance at June 30, 2022 0
Drug Product Revenue [Member] | Astellas Agreement [Member] | Japan [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (1,974)
Additions (2,226)
Reclassified to Accrued Liability 4,200
Recognized as Revenue 0
Balance at June 30, 2022 0
Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (25,891)
Additions (72,409)
Reclassified to Accrued Liability 43,273
Recognized as Revenue 90
Balance at June 30, 2022 $ (54,937)